Skip to main content

Advertisement

SpringerLink
Log in

Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

In the pre-imatinib era, treatment outcomes of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) were dismal. Despite the use of intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), complete remission and overall survival rates were less than 70% and 20%, respectively. However, imatinib, in combination with conventional chemotherapy, has dramatically changed outcomes, producing approximately 95% complete remission and 50% overall survival with or without allogeneic HSCT. Current research is now focusing on how to prevent relapse. Improvement of postremission therapy is indispensable. Although allogeneic HSCT during first complete remission is still the first choice for feasible patients, post-HSCT imatinib therapy and imatinib plus chemotherapy combinations should also be studied. New BCR-ABL tyrosine kinase inhibitors are expected to improve outcomes in imatinib-resistant leukemia. Our hope is that, in the near future, Ph-positive ALL will become a leukemia in which allogeneic HSCT is offered only for relapsed or refractory cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166–178.

    Article  PubMed  CAS  Google Scholar 

  2. Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863–871.

    Article  PubMed  CAS  Google Scholar 

  3. Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259–1266.

    Article  PubMed  CAS  Google Scholar 

  4. Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464–2471.

    Article  PubMed  CAS  Google Scholar 

  5. Hunault M, Harousseau JL, Delain M, et al.: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004, 104:3028–3037.

    Article  PubMed  CAS  Google Scholar 

  6. Kantarjian H, Thomas D, O’Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788–2801.

    Article  PubMed  CAS  Google Scholar 

  7. Thomas X, Boiron JM, Huguet F, et al.: Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22:4075–4086.

    Article  PubMed  CAS  Google Scholar 

  8. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006, 134–141.

  9. Larson RA, Dodge RK, Burns CP, et al.: A five drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025–2037.

    PubMed  CAS  Google Scholar 

  10. The Group Francais de Cytogenetique Hematologique: Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996, 87:3135–3142.

    Google Scholar 

  11. Secker-Walker LM, Prentice HG, Durrant J, et al.: Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA: MRC Adult Leukaemia Working Party. Br J Haematol 1997, 96:601–610.

    Article  PubMed  CAS  Google Scholar 

  12. Ueda T, Miyawaki S, Asou N, et al.: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998, 68:279–289.

    Article  PubMed  CAS  Google Scholar 

  13. Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983–3993.

    PubMed  CAS  Google Scholar 

  14. Thomas X, Danaila C, Le QH, et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15:1811–1822.

    PubMed  CAS  Google Scholar 

  15. Gleissner B, Gokbuget N, Bartram CR, et al.: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99:1536–1543.

    Article  PubMed  CAS  Google Scholar 

  16. Hermans A, Heisterkamp N, von Linden M, et al.: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987, 51:33–40.

    Article  PubMed  CAS  Google Scholar 

  17. Chan LC, Karhi KK, Rayter SI, et al.: A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987, 325:635–637.

    Article  PubMed  CAS  Google Scholar 

  18. Clark SS, McLaughlin J, Timmons M, et al.: Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988, 239:775–777.

    Article  PubMed  CAS  Google Scholar 

  19. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082.

    Article  PubMed  CAS  Google Scholar 

  20. Faderl S, Kantarjian HM, Thomas DA, et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000, 36:263–273.

    Article  PubMed  CAS  Google Scholar 

  21. Radich JP: Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001, 15:21–36.

    Article  PubMed  CAS  Google Scholar 

  22. Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005, 118–122.

  23. Thomas DA: Philadelphia chromosome-positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007, 435–443.

  24. Schrappe M, Arico M, Harbott J, et al.: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92:2730–2741.

    PubMed  CAS  Google Scholar 

  25. Roy A, Bradburn M, Moorman AV, et al.: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005, 129:35–44.

    Article  PubMed  Google Scholar 

  26. Barrett AJ, Horowitz MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992, 79:3067–3070.

    PubMed  CAS  Google Scholar 

  27. Stockschlader M, Hegewisch-Becker S, Kruger W, et al.: Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995, 16:663–667.

    PubMed  CAS  Google Scholar 

  28. Sierra J, Radich J, Hansen JA, et al.: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997, 90:1410–1414.

    PubMed  CAS  Google Scholar 

  29. Snyder DS, Nademanee AP, O’Donnell MR, et al.: Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999, 13:2053–2058.

    Article  PubMed  CAS  Google Scholar 

  30. Cornelissen JJ, Carston M, Kollman C, et al.: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001, 97:1572–1577.

    Article  PubMed  CAS  Google Scholar 

  31. Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357–2366.

    Article  PubMed  CAS  Google Scholar 

  32. Esperou H, Boiron JM, Cayuela JM, et al.: A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003, 31:909–918.

    Article  PubMed  CAS  Google Scholar 

  33. Iida H, Sao H, Kitaor K, et al.: Twenty years’ experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 2004, 79:79–84.

    Article  PubMed  Google Scholar 

  34. Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993) [abstract]. Blood 2001, 98:856a.

  35. Chao NJ, Blume KG, Forman SJ, Snyder DS: Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995, 85:3353–3354.

    PubMed  CAS  Google Scholar 

  36. Avivi I, Goldstone AH: Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 2003, 31:623–632.

    Article  PubMed  CAS  Google Scholar 

  37. Tanimoto M, Miyawaki S, Ino T, et al.: Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 1998, 68:421–429.

    Article  PubMed  CAS  Google Scholar 

  38. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037.

    Article  PubMed  CAS  Google Scholar 

  39. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042.

    Article  PubMed  CAS  Google Scholar 

  40. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530–3539.

    Article  PubMed  CAS  Google Scholar 

  41. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645–652.

    Article  PubMed  CAS  Google Scholar 

  42. Talpaz M, Silver RT, Druker BJ, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928–1937.

    Article  PubMed  CAS  Google Scholar 

  43. O’Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994–1004.

    Article  PubMed  CAS  Google Scholar 

  44. Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.

    Article  PubMed  CAS  Google Scholar 

  45. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971.

    Article  PubMed  CAS  Google Scholar 

  46. Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly use antileukemic agents. Blood 2001, 97:1999–2007.

    Article  PubMed  CAS  Google Scholar 

  47. Towatari M, Yanada M, Usui N, et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004, 104:3507–3512.

    Article  PubMed  CAS  Google Scholar 

  48. Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466.

    Article  PubMed  CAS  Google Scholar 

  49. Yanada M, Takeuchi J, Sugiura I, et al.: Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008, 93:287–290.

    Article  PubMed  Google Scholar 

  50. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with Hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.

    Article  PubMed  CAS  Google Scholar 

  51. Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006, 108:1469–1477.

    Article  PubMed  CAS  Google Scholar 

  52. de Labarthe A, Rousselot P, Huguet-Rigal F, et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408–1413.

    Article  PubMed  CAS  Google Scholar 

  53. Vignetti M, Fazi P, Cimino G, et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109:3676–3678.

    Article  PubMed  CAS  Google Scholar 

  54. Ottmann OG, Wassmann B, Pfeifer H, et al.: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007, 109:2068–2076.

    Article  PubMed  CAS  Google Scholar 

  55. Delannoy A, Delabesse E, Lheritier V, et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006, 20:1526–1532.

    Article  PubMed  CAS  Google Scholar 

  56. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876–880.

    Article  PubMed  CAS  Google Scholar 

  57. Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117–125.

    Article  PubMed  CAS  Google Scholar 

  58. Hochhaus A, Kreil S, Corbin AS, et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190–2196.

    Article  PubMed  CAS  Google Scholar 

  59. Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831–843.

    Article  PubMed  CAS  Google Scholar 

  60. Pfeifer H, Wassmann B, Pavlova A, et al.: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2007, 110:727–734.

    Article  PubMed  CAS  Google Scholar 

  61. Zembutsu M, Yanada M, Hishida A: Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol 2007, 31:313–322.

    PubMed  CAS  Google Scholar 

  62. Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399–401.

    Article  PubMed  CAS  Google Scholar 

  63. O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505.

    Article  PubMed  CAS  Google Scholar 

  64. Talpaz MP, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531–2541.

    Article  PubMed  CAS  Google Scholar 

  65. Verstovsek S, Golemovic M, Kantarjian H, et al.: AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005, 104:1230–1236.

    Article  PubMed  CAS  Google Scholar 

  66. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542–2551.

    Article  PubMed  Google Scholar 

  67. Kimura S, Naito H, Segawa H, et al.: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948–3954.

    Article  PubMed  CAS  Google Scholar 

  68. Boschelli DH, Wu B, Ye F, et al.: Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem 2006, 49:7868–7876.

    Article  PubMed  CAS  Google Scholar 

  69. Harrington EA, Bebbington D, Moore J, et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262–267.

    Article  PubMed  CAS  Google Scholar 

  70. Giles FJ, Cortes J, Jones D, et al.: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500–502.

    Article  PubMed  CAS  Google Scholar 

  71. Shaoguang LI: Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008, 49:19–26.

    Article  CAS  Google Scholar 

  72. Ottmann O, Dombret H, Martinelli G, et al.: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110:2309–2315.

    Article  PubMed  CAS  Google Scholar 

  73. Dai H, Marbach P, Lemaire M, et al.: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003, 304:1085–1092.

    Article  PubMed  CAS  Google Scholar 

  74. Ottmann OG, Larson LA, Kantarjian HM: Nilotinib in Patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib [abstract]. Blood 2007, 110:2815.

    Article  CAS  Google Scholar 

  75. Wassmann B, Pfeifer H, Stadler M, et al.: Early molecular response to posttransplantation imatinib determines out-come in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, 106:458–463.

    Article  PubMed  CAS  Google Scholar 

  76. Anderlini P, Sheth S, Hicks K, et al.: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:883–884.

    Article  PubMed  Google Scholar 

  77. Carpenter PA, Snyder DS, Flowers ME, et al.: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791–2793.

    PubMed  CAS  Google Scholar 

  78. Ohno R, Asou N, Ohnishi K: Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003, 17:1454–1463.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aichi Cancer Center, 1-1 Kanokoden, Chikusaku, Nagoya, 464-8681, Japan

    Ryuzo Ohno

Authors
  1. Ryuzo Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuzo Ohno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohno, R. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Oncol Rep 10, 379–387 (2008). https://doi.org/10.1007/s11912-008-0059-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0059-y

Keywords

Search

Navigation